Myocardial perfusion in cardiac amyloidosis.
Amyloidosis
Extracellular volume
Infiltration
Ischaemia
Magnetic resonance imaging
Perfusion
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
21 Jan 2024
21 Jan 2024
Historique:
revised:
07
11
2023
received:
13
06
2023
accepted:
27
12
2023
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
22
1
2024
Statut:
aheadofprint
Résumé
Cardiac involvement is the main driver of clinical outcomes in systemic amyloidosis and preliminary studies support the hypothesis that myocardial ischaemia contributes to cellular damage. The aims of this study were to assess the presence and mechanisms of myocardial ischaemia using cardiovascular magnetic resonance (CMR) with multiparametric mapping and histopathological assessment. Ninety-three patients with cardiac amyloidosis (CA) (light-chain amyloidosis n = 42, transthyretin amyloidosis n = 51) and 97 without CA (three-vessel coronary disease [3VD] n = 47, unobstructed coronary arteries n = 26, healthy volunteers [HV] n = 24) underwent quantitative stress perfusion CMR with myocardial blood flow (MBF) mapping. Twenty-four myocardial biopsies and three explanted hearts with CA were analysed histopathologically. Stress MBF was severely reduced in patients with CA with lower values than patients with 3VD, unobstructed coronary arteries and HV (CA: 1.04 ± 0.51 ml/min/g, 3VD: 1.35 ± 0.50 ml/min/g, unobstructed coronary arteries: 2.92 ± 0.52 ml/min/g, HV: 2.91 ± 0.73 ml/min/g; CA vs. 3VD p = 0.011, CA vs. unobstructed coronary arteries p < 0.001, CA vs. HV p < 0.001). Myocardial perfusion abnormalities correlated with amyloid burden, systolic and diastolic function, structural parameters and blood biomarkers (p < 0.05). Biopsies demonstrated abnormal vascular endothelial growth factor staining in cardiomyocytes and endothelial cells, which may be related to hypoxia conditions. Amyloid infiltration in intramural arteries was associated with severe lumen reduction and severe reduction in capillary density. Cardiac amyloidosis is associated with severe inducible myocardial ischaemia demonstrable by histology and CMR stress perfusion mapping. Histological evaluation indicates a complex pathophysiology, where in addition to systolic and diastolic dysfunction, amyloid infiltration of the epicardial arteries and disruption and rarefaction of the capillaries play a role in contributing to myocardial ischaemia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: A cardiac MR imaging study. Radiology 2015;277:388-397. https://doi.org/10.1148/radiol.2015141744
Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond) 2018;18:s30-s35. https://doi.org/10.7861/clinmedicine.18-2-s30
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641-2654. https://doi.org/10.1016/S0140-6736(15)01274-X
Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J 2020;41:1439-1447. https://doi.org/10.1093/eurheartj/ehz905
Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: Cardiomyopathies that look alike. J Am Coll Cardiol 2010;55:1769-1779. https://doi.org/10.1016/j.jacc.2009.12.040
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596. https://doi.org/10.1056/NEJMra023144
Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-361. https://doi.org/10.1016/j.pcad.2009.11.007
Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: Analysis of 54 necropsy patients. Am J Cardiol 1983;52:137-146. https://doi.org/10.1016/0002-9149(83)90084-x
Larsen BT, Mereuta OM, Dasari S, Fayyaz AU, Theis JD, Vrana JA, et al. Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: A histological and proteomic analysis of 108 cases. Histopathology 2016;68:648-656. https://doi.org/10.1111/his.12793
Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 2018;71:2919-2931. https://doi.org/10.1016/j.jacc.2018.03.536
Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M, et al. Myocardial perfusion cardiovascular magnetic resonance: Optimized dual sequence and reconstruction for quantification. J Cardiovasc Magn Reson 2017;19:43. https://doi.org/10.1186/s12968-017-0355-5
Kotecha T, Martinez-Naharro A, Boldrini M, Knight D, Hawkins P, Kalra S, et al. Automated pixel-wise quantitative myocardial perfusion mapping by CMR to detect obstructive coronary artery disease and coronary microvascular dysfunction: Validation against invasive coronary physiology. JACC Cardiovasc Imaging 2019;12:1958-1969. https://doi.org/10.1016/j.jcmg.2018.12.022
Knott KD, Seraphim A, Augusto JB, Xue H, Chacko L, Aung N, et al. The prognostic significance of quantitative myocardial perfusion: An artificial intelligence-based approach using perfusion mapping. Circulation 2020;141:1282-1291. https://doi.org/10.1161/CIRCULATIONAHA.119.044666
Kotecha T, Chacko L, Chehab O, O0027Reilly N, Martinez-Naharro A, Lazari J, et al. Assessment of multivessel coronary artery disease using cardiovascular magnetic resonance pixelwise quantitative perfusion mapping. JACC Cardiovasc Imaging 2020;13:2546-2557. https://doi.org/10.1016/j.jcmg.2020.06.041
Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2014;2:358-367. https://doi.org/10.1016/j.jchf.2014.03.009
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-2412. https://doi.org/10.1161/CIRCULATIONAHA.116.021612
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799-2806. https://doi.org/10.1093/eurheartj/ehx589
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554-1568. https://doi.org/10.1093/eurheartj/ehab072
Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757. https://doi.org/10.1200/JCO.2004.03.029
Bassingthwaighte JB, Wang CY, Chan IS. Blood-tissue exchange via transport and transformation by capillary endothelial cells. Circ Res 1989;65:997-1020. https://doi.org/10.1161/01.res.65.4.997
Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 2019;12:810-819. https://doi.org/10.1016/j.jcmg.2018.02.006
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-1579. https://doi.org/10.1161/CIRCULATIONAHA.115.016567
White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, et al. T1 mapping for myocardial extracellular volume measurement by CMR: Bolus only versus primed infusion technique. JACC Cardiovasc Imaging 2013;6:955-962. https://doi.org/10.1016/j.jcmg.2013.01.011
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165. https://doi.org/10.1093/eurheartj/ehy394
Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012;21:245-274. https://doi.org/10.1016/j.carpath.2011.10.001
Brown LAE, Onciul SC, Broadbent DA, Johnson K, Fent GJ, Foley JRJ, et al. Fully automated, inline quantification of myocardial blood flow with cardiovascular magnetic resonance: Repeatability of measurements in healthy subjects. J Cardiovasc Magn Reson 2018;20:48. https://doi.org/10.1186/s12968-018-0462-y
Brown LAE, Gulsin GS, Onciul SC, Broadbent DA, Yeo JL, Wood AL, et al. Sex- and age-specific normal values for automated quantitative pixel-wise myocardial perfusion cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging 2023;24:426-434. https://doi.org/10.1093/ehjci/jeac231
Gulati A, Ismail TF, Ali A, Hsu LY, Gonçalves C, Ismail NA, et al. Microvascular dysfunction in dilated cardiomyopathy: A quantitative stress perfusion cardiovascular magnetic resonance study. JACC Cardiovasc Imaging 2019;12:1699-1708. https://doi.org/10.1016/j.jcmg.2018.10.032
Goodwill AG, Dick GM, Kiel AM, Tune JD. Regulation of coronary blood flow. Compr Physiol 2017;7:321-382. https://doi.org/10.1002/cphy.c160016